ChemoCentryx, Inc. (CCXI) News

ChemoCentryx, Inc. (CCXI): $26.76

1.98 (+7.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CCXI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter CCXI News Items

CCXI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CCXI News Highlights

  • For CCXI, its 30 day story count is now at 6.
  • Over the past 19 days, the trend for CCXI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • ENTA, SAIA and VIEW are the most mentioned tickers in articles about CCXI.

Latest CCXI News From Around the Web

Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.

ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-

Yahoo | February 23, 2022

ChemoCentryx (CCXI) Receives a Buy from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on ChemoCentryx (CCXI – Research Report), with a price target of $101.00. The company's shares closed last Tuesday at $31.51. According to TipRanks.com, White 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 32.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics. ChemoCentryx has an analyst consensus of Strong Buy, with a price target consensus of $62.75, implying a 101.9% upside from current levels.

Brian Anderson on TipRanks | February 15, 2022

ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th at 5:00 p.m. Eastern Time.

GlobeNewswire | February 9, 2022

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 8, 2022

Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ...

Investment company Lisanti Capital Growth, LLC (Current Portfolio) buys Saia Inc, Knight-Swift Transportation Holdings Inc, Cytokinetics Inc, ArcBest Corp, Inspire Medical Systems Inc, sells CommVault Systems Inc, Varonis Systems Inc, Sprout Social Inc, Acadia Healthcare Co Inc, Crocs Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lisanti Capital Growth, LLC.

Yahoo | February 4, 2022

ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis

Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.

Yahoo | January 20, 2022

ChemoCentryx (CCXI) Received its Third Buy in a Row

After Stifel Nicolaus and Leerink Partners gave ChemoCentryx (NASDAQ: CCXI) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Edward White maintained a Buy rating on ChemoCentryx today and set a price target of $101.00. The company's shares closed last Wednesday at $32.73. According to TipRanks.com, White is a 2-star analyst with an average return of 1.3% and a 32.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Currently, the analyst consensus on ChemoCentryx is a Strong Buy with an average price target of $72.20, a 135.2% upside from current levels.

Catie Powers on TipRanks | January 19, 2022

Why ChemoCentryx Shares Are Rising

ChemoCentryx Inc (NASDAQ: CCXI ) shares are Full story available on Benzinga.com

Benzinga | January 19, 2022

ChemoCentryx''s Avacopan Scores European Approval For ANCA-Associated Vasculitis

The European Union has approved ChemoCentryx Inc''s (NASDAQ: CCXI ) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021 . The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis Full story available on Benzinga.com

Benzinga | January 19, 2022

ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis

The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021. The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. Related: EXCLUSIVE: ChemoCentryx Plans To Start Phase 3 Avacopan Trial In Chronic Skin Diso

Yahoo | January 19, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.588 seconds.